Recent advances in genome editing for cardiovascular disease
Purpose of review This review highlights recent progress in applying genome editing to the study and treatment of cardiovascular disease (CVD). Recent findings Recent work has shown that genome editing can be used to determine the pathogenicity of variants of unknown significance in patient-derived induced pluripotent stem cells. These cells can also be used to test therapeutic genome editing approaches in a personalized manner. Somatic genome editing holds great promise for the treatment of CVD, and important proof of concept experiments have already been performed in animal models. Here we briefly review recent progress in patient-derived cells, as well as the development of somatic genome-editing therapies for CVD, with a particular focus on liver and heart. Summary Translating this technology into the clinic will require precise editing enzymes, efficient delivery systems, and mitigation of off-target events and immune responses. Further development of these technologies will improve diagnostics and enable permanent correction of some of the most severe forms of CVD.
Conclusion: The full regeneration of solar elastosis was obtained by injection of in vitro expanded autologous adipose mesenchymal stem cells, which are appropriate, competent, and sufficient to elicit the full structural regeneration of the sun-aged skin. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
No abstract available
No abstract available
Data offers valuable resource for developing stem cell-based therapies for hearing loss
Publication date: Available online 27 May 2020Source: Stem Cell ResearchAuthor(s): Yunpan Li, David P. Ibañez, Wenxia Fan, Ping Zhao, Shuhan Chen, Mazid Md. Abdul, Zhiwei Luo, Zhenhua Liu, Jifeng Guo, Giacomo Volpe, Shahzina Kanwal, Dongye Wang, Beisha Tang, Wenjuan Li
Publication date: Available online 26 May 2020Source: Materials Science and Engineering: CAuthor(s): Gyeongju Kim, Yuna Jung, Kanghee Cho, Hyun Jong Lee, Won-Gun Koh
On May 14, 2020, Pluristem Therapeutics Inc. published follow-up data on patients treated under their compassionate use program. These patients were all being treated for with Acute Respiratory Distress Syndrome (ARDS) associated with the SARS-CoV-2 virus, and in intensive care units requiring mechanical ventilation. As of the publication date, 18 patients have been treated with PLX cells, allogeneic mesenchymal-like cells derived from human placentas after the delivery of full-term healthy babies. The patients treated include one patient in the United States. This patient received the treatment as part of the FDA Single P...
Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS ® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).“The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while als...
We present a case of this rare syndrome after autologous stem cell transplant.
Contributors : Hideko Sone ; Tomohiro ItoSeries Type : Expression profiling by arrayOrganism : Homo sapiensTo develop molecular indicators of neurodevelopmental disorders related to the exposure to external chemicals, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to influence neuronal differentiation from embryonic stem cells. Thalidomide (TMD), bisphenol A (BPA), 4-hydroxy-2,2',3,4',5,5',6-heptachlorobiphenyl (4OH-PCB187) and 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) were exposed to human embryonic stem (ES) cell-derived sphere on day 3 after s...